Esperion Therapeutics, Inc. Board of Directors

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Mr. Sheldon L. Koenig

Mr. Sheldon L. Koenig

President, CEO & Director

Mr. Glenn P. Brame

Mr. Glenn P. Brame

Chief Technical Operations Officer

Mr. Eric J. Warren R.Ph.

Mr. Eric J. Warren R.Ph.

Chief Commercial Officer

Tiffany Aldrich M.B.A.

Tiffany Aldrich M.B.A.

Associate Director of Corporate Communications

Mr. Benjamin O. Looker J.D.

Mr. Benjamin O. Looker J.D.

General Counsel & Corporate Secretary

Ms. Betty Jean Swartz

Ms. Betty Jean Swartz

Chief Business Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.